Intrinsic Value Partners LLC Sells 15,137 Shares of Moderna, Inc. (NASDAQ:MRNA)

Intrinsic Value Partners LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 29.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 36,255 shares of the company's stock after selling 15,137 shares during the quarter. Moderna comprises approximately 1.5% of Intrinsic Value Partners LLC's portfolio, making the stock its 18th biggest position. Intrinsic Value Partners LLC's holdings in Moderna were worth $1,507,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of MRNA. Wilmington Savings Fund Society FSB raised its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the period. Blue Trust Inc. boosted its stake in shares of Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after buying an additional 388 shares during the last quarter. EMC Capital Management boosted its stake in shares of Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company's stock worth $52,000 after buying an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after acquiring an additional 317 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

MRNA has been the topic of several research reports. Leerink Partners dropped their target price on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research report on Thursday, January 16th. Barclays downgraded shares of Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $111.00 to $45.00 in a report on Tuesday. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and reduced their target price for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. UBS Group dropped their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Bank of America decreased their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Moderna presently has an average rating of "Hold" and a consensus target price of $60.63.

Moderna Trading Up 0.4 %

MRNA traded up $0.15 during trading on Wednesday, hitting $35.90. 10,028,053 shares of the company traded hands, compared to its average volume of 12,961,786. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The stock's 50-day simple moving average is $38.35 and its two-hundred day simple moving average is $53.34. The company has a market cap of $13.82 billion, a PE ratio of -3.87 and a beta of 1.59.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Corporate insiders own 15.20% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.